Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population (NCT05157113)
Evaluating the Efficacy, Compliance, and Patient Satisfaction of a New Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population
🩺 Plain-English Summary (8th-Grade Level)
The current postoperative cataract surgery eye drop regimen used at Zuckerberg San Francisco General Hospital (ZSFG) is a significant burden for its patient population, contributing to high rates of non-adherence and the development of postoperative complications. The investigators propose to replace this complex regimen with a single administration of intraocular antibiotic and subconjunctival steroid at the time of surgery. This pilot study will obtain the preliminary data required to eventually fully evaluate this innovation in postoperative care in a safety-net population with respect to postoperative outcomes, patient compliance, and patient and caregiver satisfaction.
Who can join: Review the eligibility criteria below.
Location: Zuckerberg San Francisco General Hospital and Trauma Center (ZSFG) — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Zuckerberg San Francisco General Hospital and Trauma Center (ZSFG) — San Francisco, California
📞 Contact the Study Coordinator
Phone: (415) 514-0241
Email: sriranjani.padmanabhan@ucsf.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cataract
- Clinical Study of a Fluid Accommodating Intraocular Lens (IOL) Design — San José,
- Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution — Glendale, Arizona
- Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement — Babylon, New York
- A Prospective, Single-Arm Clinical Evaluation of Visual, Refractive, and Patient-Reported Outcomes Following Bilateral Implantation of the TECNIS PureSee™ Extended Depth of Focus Intraocular Lens — Sioux Falls, South Dakota
- Visual Acuity Outcome Differences Between the Alcon Vivity Toric IOL and RxSight LAL+ — Bradenton, Florida
- Visual Outcomes of Tecnis Symfony Opti-Blue EDOF Intraocular Lens (IOL) — Greenwich, Connecticut
Explore by condition: All Cataract clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.